A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Enzalutamide (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 22 Sep 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Sep 2020.
- 22 Sep 2016 Status changed from not yet recruiting to recruiting.